Ventricular Septal Defect (VSD) Closure — Cost, Top Hospitals & Success Rates | MyMedicPlus

A ventricular septal defect (VSD) is a congenital (present from birth) or acquired hole in the interventricular septum — the thick muscular partition dividing the heart's two pumping chambers, the left and right ventricles. VSDs are the single most common structural congenital heart defect, diagnosed in approximately 3–5 infants per 1,000 live births. They represent 30–40% of all congenital heart diseases (CHD) worldwide.

Normally, the interventricular septum is intact, ensuring that oxygenated blood (from the left ventricle) and deoxygenated blood (from the right ventricle) are kept entirely separate. In a VSD, blood shunts from the left ventricle (higher pressure) through the defect into the right ventricle (lower pressure) — a left-to-right shunt. This excess blood is pumped to the lungs, creating pulmonary overcirculation, volume overloading the left heart, and over time exposing the pulmonary vasculature to abnormally high pressures.

The long-term consequences of an untreated large VSD are serious: progressive pulmonary arterial hypertension (PAH), right ventricular failure, atrial and ventricular arrhythmias, infective endocarditis, and ultimately Eisenmenger syndrome — a state of irreversible pulmonary vascular disease where shunt direction reverses and closure is no longer possible. Early recognition and appropriately timed closure prevents these complications and restores normal cardiac physiology.

VSDs are classified by their anatomical location in the interventricular septum: perimembranous (most common, ~70%), muscular (~20%), outlet/supracristal (~5–7%), and inlet/AV canal type (~5%). Each type has specific characteristics that influence the choice of closure technique, the complexity of repair, and the associated risks. This comprehensive guide covers every aspect of VSD closure to support informed decision-making by patients, parents, and healthcare providers.

VSD closure procedures are applied to a spectrum of presentations, ranging from the asymptomatic neonate discovered on routine examination to the infant in florid heart failure and the adult with a long-standing unrepaired defect:

Congenital VSD in Infants and Children

• Large VSD (non-restrictive): Equalization of pressure between both ventricles; marked pulmonary overcirculation causing congestive heart failure in the first weeks to months of life. Presents with tachypnoea, poor feeding, excessive sweating, failure to thrive, and recurrent respiratory infections. Requires early surgical or transcatheter repair.
• Moderate VSD: Pulmonary-to-systemic flow ratio (Qp:Qs) typically 1.5–2.5:1; moderate LV volume overload; may cause symptoms but many children tolerate well in early childhood. Repair recommended before pulmonary hypertension becomes established, usually by age 2.
• Small (restrictive) VSD: High-pressure gradient across the defect limits shunting; Qp:Qs <1.5:1; frequently asymptomatic. Many close spontaneously. Surgical intervention not generally required unless associated with aortic regurgitation, recurring endocarditis, or outlet location.

Congenital VSD in Adults

Unrepaired VSDs presenting in adulthood are usually small to moderate, as large defects presenting in childhood are typically repaired early. Adults may present with exercise intolerance, new-onset arrhythmias (atrial fibrillation), progressive LV dysfunction, or infective endocarditis. Careful hemodynamic assessment including catheterization is essential before closure decisions are made.

Post-Myocardial Infarction (Post-MI) VSD

A catastrophic mechanical complication of acute ST-elevation MI, occurring in 0.2–0.3% of MI patients — usually within 1–5 days of infarction. Septal rupture causes acute VSD with sudden haemodynamic decompensation and cardiogenic shock. Without intervention, in-hospital mortality approaches 90%. Timing of closure (emergency vs. delayed after stabilization) is highly debated; transcatheter and surgical approaches are both used, often with bridging mechanical circulatory support.

Traumatic VSD

Blunt or penetrating cardiac trauma can lacerate the interventricular septum, creating an acquired VSD. These typically require repair once the patient is haemodynamically stable, often weeks after the acute injury.

Patient selection for VSD closure is guided by symptoms, echocardiographic and haemodynamic findings, and the specific defect characteristics:

Class I Indications (Closure Recommended)

• Symptomatic VSD with congestive heart failure or failure to thrive, regardless of defect size, in infants and children
• VSD with Qp:Qs ratio > 2:1 and pulmonary vascular resistance (PVR) < 2/3 of systemic vascular resistance (SVR)
• Evidence of LV volume overload on echocardiography or CMR (LV end-diastolic volume index > 2 SD above normal)
• Any outlet (supracristal) VSD, regardless of size, due to progressive aortic valve regurgitation risk
• VSD with associated significant aortic regurgitation or prolapse
• VSD with prior history of infective endocarditis

Class IIa Indications (Closure Reasonable)

• Moderate restrictive VSD with Qp:Qs 1.5–2:1 with evidence of LV volume overload and normal or mildly elevated PVR
• Asymptomatic adults with perimembranous VSD and right or left ventricular volume overload

Absolute Contraindication

• Eisenmenger syndrome with fixed PVR > 8 Wood units or PVR/SVR ratio > 0.67 and net right-to-left shunting: closure is contraindicated and would precipitate acute right heart failure. Advanced pulmonary vasodilator therapy or transplantation are the options for these patients.

Pre-operative Workup

Pre-operative evaluation includes: detailed echocardiography (TTE and TEE); cardiac catheterization to measure PVR in cases of suspected elevated pulmonary pressures; cardiac MRI to quantify Qp:Qs and ventricular volumes; coronary angiography in adults over 40 years to assess for concomitant coronary artery disease; and ECG to identify pre-existing conduction defects.

VSD closure is performed using two principal strategies, each with specific indications, advantages, and limitations:

Open Surgical Repair

The established gold standard for most VSDs. Performed under general anesthesia using median sternotomy (midline chest incision) and cardiopulmonary bypass (CPB). The aorta is cross-clamped, and cold crystalloid or blood cardioplegia is administered to stop the heart in diastole. The surgeon approaches the VSD through an incision in the right atrium (transatrial approach — preferred for perimembranous and inlet VSDs), the right ventricle (transventricular approach — used for muscular VSDs), or through the aorta (transaortic — for outlet VSDs).

Closure technique:

• Primary suture closure: For small, well-defined defects with firm fibrous rims; interrupted pledgeted sutures are placed around the margin
• Patch closure: For moderate to large defects; a Dacron (polyester), polytetrafluoroethylene (PTFE/Gore-Tex), or autologous/bovine pericardial patch is sutured over the defect using a running or interrupted technique

Minimally invasive approaches (right mini-thoracotomy, robotic assistance, sub-xiphoid access) are offered at specialized centres and reduce sternal morbidity, blood transfusion requirements, and recovery time.

Transcatheter Device Closure

Indicated for suitable muscular and selected perimembranous VSDs in patients weighing more than 5 kg. Performed under general anesthesia with combined fluoroscopic and echocardiographic (TEE or intracardiac echo) guidance. A long delivery sheath is advanced via femoral venous access across the atrial septum and through the VSD. A self-expandable nitinol wire mesh double-disc device (such as the Amplatzer Muscular VSD Occluder, GORE CARDIOFORM Septal Occluder, or Lifetech Cera Muscular VSD Occluder) is deployed to straddle the defect. Over 4–6 months, native tissue grows into the device mesh, achieving permanent, complete occlusion.

Device selection is guided by VSD location: Amplatzer Membranous VSD Occluder (now withdrawn in many markets due to heart block risk) vs. newer asymmetric or eccentric designs for perimembranous VSDs. Multiple muscular VSDs can sometimes be closed in a single catheterization session with multiple devices.

Hybrid Procedure

Combines surgical access (via sternotomy or thoracotomy, without CPB) with catheter-delivered device closure under direct vision and echocardiographic guidance. Used for multiply Swiss-cheese muscular VSDs in small or premature neonates in whom full CPB carries unacceptably high risk. Eliminates the risks of CPB while providing precise device positioning.

Staged Repair

In complex VSDs associated with other intracardiac defects (tetralogy of Fallot, transposition of great arteries), the VSD is repaired as part of a staged or complete repair of the underlying syndrome. The approach is individualized based on the overall anatomy and the infant's clinical status.

Successful VSD closure, performed at the right time and by experienced operators, delivers profound physiological and clinical benefits that extend across a lifetime:

Immediate Haemodynamic Benefits

• Elimination of the shunt: Left-to-right shunting ceases immediately after closure, removing the excess volume burden from the right heart and pulmonary circulation.
• Reduction in pulmonary artery pressure: In patients with elevated but reversible PAP, pressures begin to fall within hours to days of successful closure, with normalization over weeks to months.
• Left ventricular remodeling: Chronic LV volume overload resolves, leading to progressive reduction in LV end-diastolic diameter and improvement or normalization of LV function over 6–12 months.

Symptom Relief

• Rapid resolution of heart failure symptoms: breathlessness, poor feeding, sweating, and failure to thrive in infants improve dramatically within weeks of repair
• Improved exercise capacity and quality of life in children and adults
• Resolution of recurrent pulmonary infections caused by pulmonary overcirculation

Prevention of Long-term Complications

• Prevention of irreversible pulmonary vascular disease (Eisenmenger syndrome) — the most important long-term benefit of timely closure
• Prevention of progressive aortic regurgitation in outlet and perimembranous VSDs
• Reduction in endocarditis risk
• Prevention of atrial and ventricular arrhythmias due to chronic LV dilation

Transcatheter-Specific Benefits

Compared to open surgery, device closure offers avoidance of CPB, smaller access wounds (no sternotomy), shorter ICU and hospital stays, faster return to normal activities, and reduced blood transfusion requirements — all important advantages particularly valued by adult patients.

VSD closure is a safe procedure in expert hands, but carries procedure-specific risks that patients and families should understand:

Surgical Repair Risks

• Complete atrioventricular block (CAVB): The most feared complication. Damage to the His bundle or AV node during suture placement near the membranous septum occurs in 1–5% of perimembranous VSD repairs. Transient CAVB usually resolves within 7–10 days with temporary pacing wires. Persistent CAVB requires permanent pacemaker implantation (0.5–1%).
• Residual VSD: Small residual shunts through or around the patch occur in 5–10%; the majority are clinically insignificant. A significant residual defect may require reoperation (1–3%).
• Aortic regurgitation: Sutures near the aortic valve can distort the valve leaflets; careful technique minimizes this risk.
• Tricuspid regurgitation: Sutures placed through the septal leaflet of the tricuspid valve during a transatrial approach may affect valve function.
• Perioperative mortality: Less than 1% for isolated VSD repair in elective settings at experienced centres; rises to 5–10% in infants with complex associated defects or with acute post-MI VSD.
• Neurological injury: Stroke or neurodevelopmental effects from CPB; significantly reduced with modern CPB management and cerebral perfusion strategies.

Transcatheter Device Risks

• Heart block: Risk with membranous VSD devices (2–5%) due to device proximity to the conduction system; lower with muscular VSD occluders
• Device embolization: Rare but requires emergency surgical or catheter retrieval
• Haemolysis: Due to turbulent flow through incompletely closed defect; usually resolves with complete closure
• Tricuspid or aortic valve interference: Device impingement on valve leaflets may worsen regurgitation
• Incomplete closure (residual shunt): Small shunts around the device are common early; most resolve with endothelialization

Careful post-operative management and structured long-term follow-up are integral to optimal outcomes after VSD closure:

Immediate Post-operative Management

After open-heart surgery, the child or adult is transferred to the cardiac intensive care unit (CICU). Temporary epicardial pacing wires are routinely placed during surgery to manage any conduction disturbances. Mechanical ventilation is typically withdrawn within 4–12 hours in uncomplicated repairs. Vasopressor and inotropic support is weaned as cardiac function is confirmed on post-operative echocardiography. Chest drains are removed within 24–48 hours once drainage is minimal.

After transcatheter closure, the patient is monitored in a cardiac step-down unit for 24–48 hours with telemetry to detect arrhythmias or heart block. Echocardiography is performed before discharge to confirm device position and assess for residual shunting or valve impingement.

Post-discharge Care

• Medications: Aspirin 3–5 mg/kg/day (max 100 mg) for 6 months after device closure. Diuretics are continued for 4–6 weeks post-surgery then weaned as ventricular remodeling occurs.
• Wound care: Sternal wound hygiene and skin care; sternal precautions for 6–8 weeks in adults (no pushing or pulling with arms).
• Diet and activity: Infants resume normal feeding promptly; age-appropriate activity restrictions for 6–8 weeks followed by gradual return to sport and physical education.

Structured Follow-up Schedule

• 4–6 weeks post-discharge: Echocardiography to assess residual shunt, LV dimensions, PAP, and device/patch integrity; ECG to evaluate AV conduction
• 6 months: Reassessment of LV remodeling; endothelialization confirmed (device closure); formal decision on IE prophylaxis continuation
• Annual (for life): Echocardiogram and ECG; assessment for late arrhythmias (AF, complete heart block), aortic regurgitation, or residual shunt

The majority of patients who have an isolated VSD closed in childhood achieve a normal adult life with no functional restrictions. Annual follow-up at an adult congenital heart disease (ACHD) centre is recommended for life to monitor for late complications.

VSD closure costs are significant but are offset by the burden of untreated disease. Here is an overview of the financial considerations:

Factors Affecting Cost

• Closure method: Open surgical repair is typically more expensive than transcatheter device closure due to CPB costs and longer hospital stay, but device costs can partially offset this
• Patient complexity: Neonates, premature infants, patients with pulmonary hypertension, or those undergoing repair with associated defects (AV canal, tetralogy) incur higher costs
• Hospital tier: Academic/tertiary centres vs. secondary hospitals; private vs. public sector
• Post-operative ICU stay duration
• Geographic location

Global Cost Estimates

• United States: USD 40,000–100,000 for open surgical repair (all-in hospital + surgeon + anesthesia); USD 25,000–55,000 for transcatheter closure. Covered by Medicaid, CHIP, and most private insurance plans for congenital heart disease.
• United Kingdom: NHS covers all costs for UK children and eligible adults. Private: GBP 18,000–40,000.
• India: USD 3,500–9,000 for surgical VSD repair at NABH-accredited hospitals; USD 2,000–5,000 for device closure. Leading centres: AIIMS, Narayana Hrudayalaya (Bangalore), Apollo Hospitals, Sri Jayadeva Institute of Cardiovascular Sciences. India attracts significant medical tourism for congenital heart surgery due to world-class expertise at a fraction of Western costs.
• Singapore: USD 15,000–30,000 — National Heart Centre Singapore is a regional hub for complex CHD
• Thailand: USD 9,000–20,000 — Bumrungrad International Hospital, Bangkok Heart Hospital
• Malaysia: USD 7,000–15,000 — Institut Jantung Negara (National Heart Institute)
• Turkey: USD 6,000–14,000 — growing expertise in congenital cardiac surgery

Financial Assistance

Many countries operate government-funded schemes or cardiac surgery foundations for children with congenital heart disease. In India, the Rashtriya Bal Swasthya Karyakram (RBSK) and state government schemes fund VSD repair for eligible children. International foundations such as the Chain of Hope and Save a Child's Heart provide surgical support in low-income countries.

In specific clinical contexts, non-surgical alternatives or adjunctive therapies play an important role:

Observation and Spontaneous Closure Monitoring

For small, restrictive, hemodynamically insignificant VSDs — particularly muscular defects in infants — a strategy of active surveillance with echocardiography every 6–12 months is appropriate. Spontaneous closure occurs in the majority of small muscular VSDs and a significant proportion of small perimembranous VSDs. Parents receive education regarding warning signs (increased breathing difficulty, poor feeding, recurrent chest infections) that should prompt earlier re-evaluation.

Medical Therapy for Heart Failure (Bridge to Surgery)

Infants with large VSDs and congestive heart failure are started on medical therapy to optimize their condition before surgery. Standard regimen includes: furosemide (loop diuretic), spironolactone (potassium-sparing diuretic), captopril or enalapril (ACE inhibitor to reduce afterload and Qp:Qs), and high-calorie nutritional supplementation to promote growth. This approach does not cure the defect but stabilizes the infant for safer surgical repair.

Pulmonary Artery Banding

Rarely used in contemporary practice as a palliative measure in complex scenarios (e.g., multiple Swiss cheese muscular VSDs in a neonate too small for device closure, or complex VSD + other cardiac anomalies requiring staged repair). A surgical band is placed around the main pulmonary artery to restrict pulmonary blood flow and protect the pulmonary vasculature until definitive VSD repair is feasible.

Pulmonary Vasodilator Therapy (for Eisenmenger Syndrome)

Patients who present late with established Eisenmenger syndrome cannot undergo VSD closure. Pulmonary vasodilator therapy with endothelin receptor antagonists (bosentan, macitentan), PDE-5 inhibitors (sildenafil, tadalafil), or prostacyclin analogues improves functional class, 6-minute walk distance, and quality of life, and may modestly improve survival. Heart-lung transplantation (or heart transplant with bilateral lung transplant) remains the only curative option for this end-stage complication.

Transcatheter vs. Surgical Approach

In patients who are eligible for both methods, the choice between transcatheter device closure and open surgery should be made after careful multidisciplinary discussion considering defect anatomy, centre expertise, patient preference, and the risk-benefit profile of each approach. Both methods are valid for suitable defects, with comparable closure rates and safety in experienced hands.